Quarterly report [Sections 13 or 15(d)]

Revenues from Contracts and Significant Customers (Tables)

v3.25.1
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2025
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s net revenue for the periods presented:

​

​

​

​

​

​

​

​

​

Three Months Ended March 31, 

($ in thousands)

    

2025

    

2024

Qbrexza

​

$

5,161

​

$

5,017

Accutane

​

​

3,655

​

​

5,819

Emrosi

​

​

2,070

​

​

—

Amzeeq

​

​

1,100

​

​

755

Zilxi

​

​

426

​

​

273

Other / legacy product revenue

​

​

727

​

​

1,166

Total net revenue

​

$

13,139

​

$

13,030